CTI BioPharma
(NASDAQ:CTIC)
$5.98
At close: Dec 1(Delayed 15-Minutes)
Get Real Time Here
$5.98
After Hours: 4:01PM EDT
Day Range- - -52 Wk Range1.43 - 7.8Open / Close- / -Float / Outstanding117.7M / 126.9M
Vol / Avg.- / 3.8MMkt Cap758.8MP/E-50d Avg. Price5.41
Div / Yield-Payout Ratio-Total Float117.7MEPS-0.13

CTI BioPharma Stock (NASDAQ:CTIC), Quotes and News Summary

CTI BioPharma Stock (NASDAQ: CTIC) stock price, news, charts, stock research, profile.

Loading...
Day Range- - -52 Wk Range1.43 - 7.8Open / Close- / -Float / Outstanding117.7M / 126.9M
Vol / Avg.- / 3.8MMkt Cap758.8MP/E-50d Avg. Price5.41
Div / Yield-Payout Ratio-Total Float117.7MEPS-0.13
InvestorsObserver - Nov 22, 2022, 7:51AM
InvestorsObserver - Nov 14, 2022, 6:57AM
Seeking Alpha - Nov 8, 2022, 12:47PM
InvestorsObserver - Nov 8, 2022, 9:25AM
Seeking Alpha - Nov 6, 2022, 4:35PM
Seeking Alpha - Nov 2, 2022, 4:15PM
TalkMarkets - Oct 29, 2022, 4:34PM
InvestorsObserver - Oct 28, 2022, 9:51AM
InvestorsObserver - Oct 26, 2022, 7:47AM
InvestorsObserver - Oct 18, 2022, 8:36AM
InvestorsObserver - Oct 10, 2022, 7:35AM
InvestorsObserver - Oct 4, 2022, 11:43AM
Sector: Health Care.Industry: Biotechnology
CTI BioPharma Corp is a biopharmaceutical company focused on the acquisition, development, and commercialization of less toxic and more effective cancer therapies. Its therapeutic area is blood-related cancers. Its products under pipeline include PIXUVRI, and Pacritinib. PIXUVRI is a novel aza-anthracenedione with unique structural and physiochemical properties. Pacritinib is an investigational oral kinase inhibitor for the treatment of adult patients with myelofibrosis.

Earnings

see more
Q3 2022Est.ActualSurprise
EPS-0.160-0.130 0.0300
REV17.170M18.241M1.071M
Q2 2022Est.ActualSurprise
EPS-0.200-0.210 -0.0100
REV9.100M12.329M3.229M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy CTI BioPharma (CTIC) stock?

A

You can purchase shares of CTI BioPharma (NASDAQ: CTIC) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are CTI BioPharma's (CTIC) competitors?

Q

What is the target price for CTI BioPharma (CTIC) stock?

A

The latest price target for CTI BioPharma (NASDAQ: CTIC) was reported by SVB Leerink on Monday, October 17, 2022. The analyst firm set a price target for 13.00 expecting CTIC to rise to within 12 months (a possible 117.39% upside). 7 analyst firms have reported ratings in the last year.

Q

Current Stock Price for CTI BioPharma (CTIC)?

A

The stock price for CTI BioPharma (NASDAQ: CTIC) is $5.98 last updated December 1, 2022, 9:00 PM UTC.

Q

Does CTI BioPharma (CTIC) pay a dividend?

A

There are no upcoming dividends for CTI BioPharma.

Q

When is CTI BioPharma (NASDAQ:CTIC) reporting earnings?

A

CTI BioPharma’s Q3 earnings are confirmed for Monday, November 7, 2022.

Q

Is CTI BioPharma (CTIC) going to split?

A

There is no upcoming split for CTI BioPharma.

Q

What sector and industry does CTI BioPharma (CTIC) operate in?

A

CTI BioPharma is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.